Yahoo
ASX - Delayed Quote AUD

Clarity Pharmaceuticals Ltd (CU6.AX)

1.5700 -0.1000 (-5.99%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for CU6.AX
  • Previous Close 1.6700
  • Open 1.6500
  • Bid 1.5700 x --
  • Ask 1.5850 x --
  • Day's Range 1.5450 - 1.6650
  • 52 Week Range 1.5150 - 5.1000
  • Volume 2,799,766
  • Avg. Volume 2,332,709
  • Market Cap (intraday) 585.738M
  • Beta (5Y Monthly) 1.18
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2900
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 7.20

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

www.claritypharmaceuticals.com

100

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

CU6.AX
53.55%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

CU6.AX
67.96%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

CU6.AX
49.52%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

CU6.AX
39.56%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Analyst Insights

View More

Analyst Price Targets

5.60
7.20 Average
1.5700 Current
8.40 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.12%

  • Return on Equity (ttm)

    -77.54%

  • Revenue (ttm)

    10.53M

  • Net Income Avi to Common (ttm)

    -107.14M

  • Diluted EPS (ttm)

    -0.2900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    178.25M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -59.44M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: